Ciprofarma

Quick links to important sections

Ciprofarma

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciprofarma

What is Ciprofarma?

Ciprofarma is a pharmaceutical preparation containing ciprofloxacin, which belongs to a class of medications known as fluoroquinolone antibiotics. It is designed to address a variety of bacterial infections by interfering with the ability of bacteria to replicate and repair their genetic material.

Classification and Mechanism

As a broad-spectrum antibiotic, Ciprofarma is effective against a wide range of gram-negative and some gram-positive bacteria. It works by inhibiting specific bacterial enzymes—DNA gyrase and topoisomerase IV—which are essential for bacterial DNA synthesis. Without these enzymes, the bacteria cannot multiply, leading to the resolution of the infection.

Common Applications

Ciprofarma is typically utilized in the management of infections located in different parts of the body, including:

  • Urinary Tract: Infections affecting the bladder or kidneys.
  • Respiratory System: Certain types of pneumonia or chronic bronchitis flare-ups.
  • Skin and Soft Tissue: Bacterial infections of the skin layers.
  • Bone and Joint: Infections involving the skeletal system.
  • Abdominal Cavity: Intra-abdominal infections, often used in combination with other agents.

Therapeutic Context

Ciprofarma is specifically intended for the treatment of infections caused by bacteria. It is not effective against viral infections, such as the common cold or influenza. Use of this medication is generally reserved for situations where a healthcare professional has identified a susceptible bacterial strain to ensure the appropriate management of the condition.

Regulatory References

  1. NIH MeSH Cyproterone Acetate Classification

What side effects are possible with Ciprofarma?

Ciprofarma: Possible Side Effects and Safety Information

Critical Safety Warnings

Official regulatory documents emphasize that Ciprofarma, a fluoroquinolone antibiotic, is associated with disabling and potentially irreversible serious adverse reactions involving multiple body systems. These serious reactions include tendinitis and tendon rupture (most often the Achilles tendon), peripheral neuropathy (nerve damage that may cause pain, burning, tingling, or numbness), and Central Nervous System (CNS) effects (such as seizures, anxiety, psychosis, and suicidal thoughts). These events can occur within hours to weeks of starting treatment, and some effects may be permanent. Ciprofarma is also contraindicated in patients with a history of myasthenia gravis as it may exacerbate muscle weakness.

Other Serious Adverse Reactions

Additional warnings include the risk of Aortic Aneurysm and Dissection (a bulge or tear in the aorta, especially in the elderly), Hypersensitivity Reactions (including anaphylaxis, which can be life-threatening), Hepatotoxicity (severe liver injury, which may be fatal), and blood glucose disturbances (both hypoglycemia and hyperglycemia, particularly in diabetic patients). The medication can also cause Clostridioides difficile-associated diarrhea (CDAD), which may range from mild to severe colitis.

Common Side Effects and Monitoring

The most common adverse reactions (occurring in 1% or more of patients) involve the gastrointestinal system, and include nausea, diarrhea, and vomiting. Other common reactions are headache and rash. Patients taking Ciprofarma are advised to avoid co-administration with tizanidine, and to separate administration from products containing multivalent cations (like iron or calcium) due to reduced absorption. The drug should be discontinued immediately at the first sign of tendon pain, nerve symptoms, or CNS effects to mitigate the risk of irreversible harm.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Ciprofarma

Overdose scope

Feature Official Regulatory Statement
Documented overdose presentations No specific acute intoxication symptoms have been formally reported in man with non-fatal overdosage.
Physiological systems affected (as stated in label) The primary focus of severe risk involves the hepatic system (liver).
Dose-related or exposure-related factors (if applicable) Fatal outcomes due to hepatic toxicity have been reported at dosages of 100 mg and above.
Population-specific overdose notes (if applicable) Most reported fatal cases were in men with advanced prostatic cancer receiving high doses.
Emergency-response statements (as written in official documents) Contact the regional poison control centre. Gastric lavage can safely be used if oral overdosage is discovered within two to three hours.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention upon suspicion of overdose, especially if first signs of thrombophlebitis or thromboembolism occur.

Overdose classifications (high-level)

  • Severity classification (as defined in official documents): Overdose is classified primarily by the potential for severe toxicity, specifically hepatic failure, which includes the risk of fatal outcome.
  • Regulatory basis (EMA / FDA / etc.): Information is consistent with official regulatory prescribing information, including the Summary of Product Characteristics (SmPC).
  • Overdose-context constraints (as defined in official documents): The regulatory management profile is constrained by the fact that no specific antidote is known.

Resulting overdose structure

Official overdose statements:

  • No specific antidote is known for Ciprofarma overdose.
  • Treatment, if required, should be symptomatic and supportive.
  • Any suspected overexposure requires immediate medical evaluation due to the potential for severe, dose-related outcomes.

Connection to the overall overdose profile: The regulatory documents define the overdose profile by its absence of a known antidote and the corresponding mandate for symptomatic and supportive treatment. Emergency-seeking conditions are strictly dictated by the high potential for severe hepatic toxicity and thromboembolic events, requiring the immediate application of specialized hospital monitoring and care.

Therapeutic Uses of Ciprofarma

The medication is relevant for a specific set of androgen-dependent clinical presentations in both men and women.

Ciprofarma is primarily used to manage conditions characterized by heightened symptoms driven by androgen activity. In adult women, it is applied to address severe signs of androgenisation, including hirsutism (excessive hair growth), severe inflammatory acne, and androgenetic alopecia (pattern hair loss). In adult men, it plays a role in the palliative management of advanced, hormone-dependent prostatic carcinoma, and for the therapeutic control of severe deviations of the sexual drive (hypersexuality). The medication is relevant for easing symptoms that may become disruptive or intense. It may assist with easing their impact.

It is commonly used to help with symptom clusters that create noticeable physiological strain.”

Quick Fact: Relief for Androgen-Driven Symptoms

This medicine is considered relevant in clinical settings that involve severe or resistant androgen-related manifestations, offering support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Ciprofarma (Cyproterone Acetate) eligibility is strictly defined by regulatory documents, distinguishing between approved adult use and several absolute exclusions. The medicine is primarily allowed for use in adult men and adult women for officially approved, androgen-dependent conditions.


Populations for Whom Use is Contraindicated

Absolute prohibition from using this medicine applies to patients with:

  • A known meningioma or a history of this type of tumor.
  • Existing or previous liver diseases (including Dubin-Johnson and Rotor syndromes) or liver tumours (unless metastatic from prostate cancer).
  • A history of thromboembolic processes (blood clots).
  • Specific comorbidities, including severe chronic depression, wasting diseases, or severe diabetes with vascular changes.
  • Known hypersensitivity to the active substance or excipients.

Age and Physiological Restrictions

Category Official Regulatory Statement
Pediatric Use Not recommended for use in male children and adolescents below 18 years of age; use must not begin before the conclusion of puberty due to risks to development.
Pregnancy/Lactation Contraindicated in women who are pregnant (must be excluded before starting treatment) and during breastfeeding.
Renal Function Use in patients with renal impairment has not been specifically studied; no specific dosage adjustment data is provided in the label.

What should I know about interactions with other medicines?

Ciprofarma (ciprofloxacin) can interact with several other medications, which may lead to changes in drug effectiveness or an increased risk of side effects. It is essential to inform your healthcare provider of all prescription, over-the-counter, and herbal products you are taking.

Major Interactions: Increased Drug Levels or Effects

Interacting Medication Potential Outcome
Tizanidine (muscle relaxant) Contraindicated. Can significantly increase tizanidine levels, leading to severe low blood pressure and excessive sedation.
Theophylline (for asthma/COPD) Can increase theophylline concentrations, risking toxicity (e.g., seizures, restlessness). Requires close monitoring and possible dose adjustment.
Warfarin (blood thinner) Can potentiate the anticoagulant effect of warfarin, increasing the risk of bleeding. Requires frequent monitoring of INR/prothrombin time.
Phenytoin (for seizures) Ciprofloxacin may either increase or decrease phenytoin blood levels, potentially leading to loss of seizure control or toxicity.

Reduced Ciprofarma Absorption

Products containing multivalent cations (e.g., calcium, magnesium, aluminum, iron, or zinc) can bind to ciprofloxacin in the gut, substantially reducing its absorption and effectiveness. These products include:

  • Antacids (e.g., aluminum/magnesium hydroxide)
  • Sucralfate
  • Iron or Zinc supplements
  • Dairy products (milk, yogurt) and calcium-fortified foods

To prevent this interaction, Ciprofarma should be taken at least two hours before or six hours after these products. Intake with a meal containing small amounts of dairy, however, is generally acceptable. Ciprofarma may also increase the effects of caffeine and certain oral diabetes medications (sulfonylureas), requiring monitoring.

Mechanism of Action

How Ciprofarma Works

Ciprofarma's mechanism of action is selective, acting on key regulatory systems to reduce signal output within targeted cellular pathways. The effect initiates with a precise molecular interaction where the compound selectively engages defined receptor or enzyme systems within target cells. This action classifies Ciprofarma as a modulator that alters the activity state of these regulatory proteins by initiating or blocking specific signaling events.

This primary interaction subsequently triggers a sequence of molecular events, operating within well-characterized signaling cascades. Ciprofarma modifies early molecular steps that limit the amplification and systemic spread of dysregulated signals. This cascade intervention results in a downstream reduction in the concentration or influence of mediators and modulates activity toward basal levels within peripheral and central physiological pathways, thereby shaping the subsequent mechanistic effects. This pharmacodynamic activity is restricted to affecting defined biological targets and their associated signaling sequences, without influencing non-targeted cellular processes.

Dosage and Administration Information

How to Use Ciprofarma

This section outlines the standardized instructions for the correct administration of Ciprofarma. Adherence to these steps is essential for proper use.


Administration and Dosing Schedule

Ciprofarma is taken orally as a standard tablet, extended-release tablet, or oral suspension. Doses are typically taken twice daily (every 12 hours) or once daily for the extended-release formulation, for a full duration determined by the prescribing healthcare professional.

  • Timing: Doses must be taken at the same, evenly spaced times to maintain a consistent amount of medicine in the body. Do not stop taking the medicine before completing the full prescribed course, even if symptoms improve.
  • Missed Dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next scheduled dose, skip the missed dose and return to the regular schedule. Do not double the dose.

Administration Requirements

  • With Food: The medicine can be taken with or without food. However, it should not be taken alone with dairy products (such as milk or yogurt) or calcium-fortified juices. These foods are acceptable if consumed as part of a larger meal.
  • Physical Handling: Standard tablets must be swallowed whole or broken only at the score line if one is present, but they must not be crushed or chewed. Extended-release tablets must always be swallowed whole and never split, crushed, or chewed. The oral suspension must be shaken well for at least 15 seconds before each use and measured with a specialized device.
  • Hydration: Patients must drink plenty of fluids while taking this medication.
  • Interaction Timing: Products containing magnesium, aluminum, calcium, iron, or zinc (e.g., antacids, multivitamins) must be taken at least 2 hours before or 6 hours after Ciprofarma.

Age-Specific Rules

For pediatric patients and adults with impaired kidney function (renal impairment), the required dosage and frequency are often reduced and adjusted based on weight or kidney function tests.

Recent Clinical Evidence

Ciprofarma: Recent Clinical Evidence


Evidence for Severe Androgen-Related Symptoms in Women

Research has been evaluated through high-level studies, including Randomized Controlled Trials (RCTs) and Systematic Reviews. For severe hirsutism, studies focused on women of reproductive age, often with Polycystic Ovary Syndrome (PCOS). Researchers measured objective clinical scores (e.g., Modified Ferriman-Gallwey score) and monitored endocrine biomarker shifts, reporting a measurable change in circulating testosterone levels and a decline in objective clinical scores in observed populations. For severe inflammatory acne, studies examined short-term changes, monitoring the measurement of changes in overall acne severity grade and lesion counts. Findings described patterns of changes in lesion counts, with researchers exploring the relationship to androgen sensitivity.

Evidence for Advanced Prostatic Carcinoma in Men

The medicine was studied for its role in the palliative management of advanced, hormone-dependent prostatic carcinoma in adult men. This established evidence base includes long-term follow-up studies. Research describes that the medicine was evaluated for the antiandrogen effect, with studies monitoring key markers of disease progression and long-term functional outcomes, such as Overall Survival (OS) and shifts in the tumor biomarker Prostate-Specific Antigen (PSA) values. The long-term studies and reports spanned defined time intervals, often reaching months to years.

Evidence for Therapeutic Control of Severe Sexual Drive

The evidence base for this application is drawn primarily from small clinical experience reports and limited controlled studies. These studies monitored outcomes related to functional imbalance, such as sexual compulsivity scores and the frequency of sexual urges, alongside the objective measurement of testosterone levels. Findings indicated patterns showing changes in self-reported sexual urges and consistent changes in circulating testosterone levels.

Long-Term Data and Uncertainties

The research base provides insight into short-term changes, but the limited follow-up data suggest that long-term outcomes are not well characterized. This includes the durability of the reported effects and potential for symptom relapse. Research highlights several limitations: sample sizes were modest in many trials, and evidence is often described as heterogeneous due to a lack of standardized assessment. For certain behavioral outcomes, certainty remains low due to reliance on small trials and clinical reports.

Studies exploring short-term symptom changes have included specific groups, such as women with hirsutism that is associated with Polycystic Ovary Syndrome (PCOS). There are few data available for populations outside of the primary study groups, and specific research related to pediatric use or use in older adults without prostatic carcinoma remains limited.

Key Studies & References Cyproterone Acetate (C14316) - NIH National Library of Medicine Medical Subject Headings (MeSH)

Frequently Asked Questions (FAQ)

Common questions about Ciprofarma (FAQ)


Q: Is it normal to feel a bit nauseous after taking Ciprofarma?

According to official product information, nausea is described as a common side effect of Ciprofarma. Gastrointestinal issues such as nausea, diarrhea, and vomiting are among the most frequently reported adverse reactions, especially when first starting treatment.


Q: Can Ciprofarma cause sun sensitivity or skin reactions?

Regulatory patient information describes the possibility of increased sensitivity of the skin to sunlight while taking this medication. Official sources advise limiting exposure to sunlight and recommend the use of protective clothing and sun block.


Q: Why do official warnings mention possible effects on the heart rhythm for Ciprofarma?

Official product information, particularly for high-dose use, mentions tachycardia (a fast heartbeat) and other cardiovascular events are possible adverse effects. Warnings also highlight the risk of thromboembolism (blood clots), which is a serious event described in regulatory information.


Q: Is it true that Ciprofarma can affect how other medications, like blood thinners, work?

Yes, official warnings state that Ciprofarma can affect certain other medicines. For example, it is known to increase the anticoagulant effect of Warfarin, a common blood thinner, and Warfarin is noted to require monitoring of coagulation parameters.


Q: What is the difference between Ciprofarma tablets and the intravenous (IV) form?

Ciprofarma is available as a standard oral dosage form (tablets) that is taken by mouth, and as an injectable solution for intramuscular administration. The injectable form is noted for use in specific indications, such as those requiring a higher dose of the active ingredient.


Q: Why do doctors need to know about kidney problems before prescribing Ciprofarma?

The active ingredient is primarily excreted through the kidneys and bile. For this reason, official regulatory guidelines indicate that dosage modifications may be considered for adults with impaired kidney function.


Q: Why is there concern about Ciprofarma and blood sugar levels?

Regulatory information indicates that Ciprofarma may impair carbohydrate metabolism, which is how the body processes sugar. Because of this, careful examination of blood glucose levels is recommended during treatment, particularly for patients who have pre-existing diabetes.


Q: Does Ciprofarma make birth control less effective?

Ciprofarma used alone can cause menstrual cycle disturbances in women. When the active ingredient is used in a specific combination pill with an estrogen, it provides reliable contraception, but missed or delayed doses of the combination product may require patients to follow specific instructions outlined in the official patient information.


Q: What is the maximum duration that Ciprofarma is typically prescribed for?

The length of treatment varies widely based on the medical condition it is managing. For certain conditions, treatment is stopped once the issue has resolved. For other uses, such as advanced cancer, the medicine is described in official documentation as being used in long-term follow-up studies that span months to years.


Q: How quickly does Ciprofarma typically start working?

Official data indicates that the active ingredient is rapidly absorbed, reaching peak plasma levels in the body approximately 3 to 4 hours after oral administration. However, the time until a noticeable improvement in symptoms occurs can vary based on the patient and the condition being managed.


Q: How long after stopping Ciprofarma do the side effects usually go away?

Regulatory follow-up data for certain reversible effects provide a timeframe for recovery. For instance, effects on spermatogenesis generally revert to previous levels 3 to 5 months after treatment is stopped.


Q: What are the most common reasons why people have to stop using Ciprofarma?

Official instructions advise that the medicine must be discontinued immediately at the first sign of serious, life-threatening adverse reactions. These reactions include confirmed hepatotoxicity (severe liver injury) or signs of thrombophlebitis (blood clot formation).


Q: Can Ciprofarma change the results of certain lab tests?

Yes, official regulatory documents indicate that Ciprofarma can lead to changes in the concentrations of certain lab markers. These include levels of liver enzymes, prolactin, and sex hormones (such as testosterone).


Q: Is it okay to drink coffee or caffeine while taking Ciprofarma?

Official documents note that Ciprofarma may increase the effects of caffeine in the body. This interaction can potentially result in symptoms such as anxiety or restlessness.


Q: Does Ciprofarma have different effects on children compared to adults?

The medicine is not recommended for use in male children and adolescents below 18 years of age due to potential risks to development. Studies in children have shown the drug can cause adrenal hypofunction (reduced function of the adrenal gland).


Q: Are there generic versions of Ciprofarma available?

The active ingredient in Ciprofarma, Cyproterone Acetate, is widely available and marketed globally under various trade names. This includes both the original branded product and various generic formulations.


Q: Why do some people experience dizziness or confusion with Ciprofarma?

Regulatory patient precautions state that the medicine may cause people to become dizzy or drowsy. Official warnings also note that Ciprofarma can be associated with serious Central Nervous System (CNS) effects including confusion.


Q: Does Ciprofarma cause resistance if used too frequently?

No. Official documents classify Ciprofarma (Cyproterone Acetate) as a steroidal antiandrogen and progestin. Because it is not an antibiotic, the issue of bacterial resistance is not applicable to its intended purpose or mechanism of action.


Q: Can I stop taking Ciprofarma once I start feeling better?

Official administration instructions state: Do not stop taking the medicine before completing the full prescribed course. Stopping before completion may be associated with the return or recurrence of the underlying condition.


Q: What kind of infections does Ciprofarma NOT treat?

The approved purpose of Ciprofarma is to manage conditions driven by androgen activity (male hormones). It is not indicated for and will not treat bacterial, viral, or fungal infections.


Q: Is Ciprofarma known to interact with herbal supplements like St. John's Wort?

Official product information advises that herbal remedies can affect the efficacy of the medicine. Regulatory sources specifically note that St. John's Wort may cause a significant decrease in the blood levels of the active ingredient.


Q: What are the official guidelines regarding the use of Ciprofarma in the elderly?

Official information provides no specific comparison of use in the elderly versus other age groups. However, regulatory cautions highlight that older patients may have an increased risk of severe effects, such as a rare event involving the Aorta (a major blood vessel).


Q: Can Ciprofarma make you feel tired or fatigued?

Official product information describes both tiredness and fatigue as common general disorders. These effects are particularly noted when initiating treatment with Ciprofarma.


Q: Is it true that Ciprofarma is a type of fluoroquinolone antibiotic?

No. Despite some common drug names being confused, official documents classify Ciprofarma (Cyproterone Acetate) as a steroidal antiandrogen and progestin. It does not belong to the fluoroquinolone antibiotic class.


Q: Do studies show a connection between Ciprofarma and mental health side effects?

Yes. Regulatory warnings state the drug is associated with Central Nervous System (CNS) effects. These can include mood changes such as anxiety, psychosis, suicidal thoughts, and depressed mood.


Q: Does Ciprofarma require a prescription?

Official regulatory documentation indicates that Ciprofarma is generally classified as a prescription-only drug.


Q: Are there different strengths of Ciprofarma tablets available?

Regulatory documents confirm that Ciprofarma is available in different strengths. These include standard tablets (such as 50 mg) for certain indications and a lower dose (such as 2 mg) when used as part of a combination product.

How should Ciprofarma be stored and disposed of?

How to Store and Dispose of Ciprofarma

Official Storage Conditions

Ciprofarma (Cyproterone Acetate) tablets must be stored at room temperature and kept in the original, closed container to ensure stability.

Regulatory documents specify that the product must be protected from light and moisture and should be kept from freezing. The labeled shelf life for the unopened product is contingent upon these required storage conditions being met.


Handling and Disposal

As a mandatory safety precaution, the medicine must be stored out of the sight and reach of children.

For disposal, unused or expired Ciprofarma must not be disposed of via household waste or wastewater. The product and container must be discarded according to local, regional, or national regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciprofarma found in:

A-Z Index: